Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE limits rheumatoid arthritis drugs to severe disease

arthritis__inflamation__old__hands__xray.jpg
  • Comment

The National Institute for Health and Care Excellence has recommended a raft of new drugs for the treatment of rheumatoid arthritis, but only when the condition is severe.

In final updated guidance published today, NICE recommends seven biological disease modifying drugs as options for treating severe rheumatoid arthritis, which has not responded to intensive therapy with a combination of conventional disease-modifying anti-rheumatic drugs.

“This guidance reaffirms our previous recommendations on these drugs”

Carole Longson 

However, the guidance does not recommend their use for treating moderate active rheumatoid arthritis. Publication of the guidance follows unsuccessful appeals against the draft guidance.

The guidance recommends adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra or Remsima), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia), each in combination with methotrexate.

Adalimumab, etanercept, certolizumab pegol or tocilizumab are also recommended as monotherapy for people who cannot take methotrexate.

In the case of certolizumab pegol, golimumab, abatacept and tocilizumab the recommendation is subject to the companies providing them as agreed in their patient access schemes.

The guidance states that treatment should be started with the least expensive drug (taking into account administration costs, dose needed and product price per dose).

The guidance also includes recommendations about when treatment with biological DMARDs should be continued or withdrawn.

Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE, said: “This guidance considers at what stage it’s clinically and cost effective to start using biological therapies as treatment options for adults with rheumatoid arthritis.

“In recommending them as options for people with severe rheumatoid arthritis after previous treatment with conventional DMARDs has been unsuccessful, this guidance reaffirms our previous recommendations on these drugs and confirms their place as an integral part of the rheumatoid arthritis treatment pathway,” she said.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.